GSTM1 and endothelial dysfunction: Current and future therapies target different pathophysiological mechanisms of SCD: (a) modulation of Hb polymerization, erythrocyte dehydration, and Hb oxygen affinity; (b) prevention of vaso-occlusion by inhibiting cells interactions; (c) prevention of endothelial dysfunction; and (d) modulation of inflammation [46].